Table 3:
Changes in Immune Markers after TARE
| Cytometry Type and Marker | Pre-TARE Level | Post-TARE Level | Relative Difference | P Value |
|---|---|---|---|---|
|
| ||||
| Peripheral blood flow cytometry | ||||
| No. of participants | 17 | 17 | ||
| IL-10 (pg/mL) | 0.2 (1.7) | 0.4 (2.0) | 1.9 (1.4, 2.7) | .001 |
| IL-6 (pg/mL) | 1.0 (3.8) | 1.6 (3.8) | 1.6 (1.1, 2.4) | .02 |
| IL-8 (pg/mL) | 13.5 (3.7) | 15.6 (3.9) | 1.2 (0.9, 1.5) | .30 |
| IL-15 (pg/mL) | 1.9 (1.7) | 2.4 (1.5) | 1.3 (1.1, 1.6) | .01 |
| Monocytes (%) | 18 (2) | 20 (2) | 1 (1, 2) | .81 |
| Myeloid-derived suppressor cells (%) | 3 (2) | 3 (2) | 1 (1, 2) | .64 |
| Tumor biopsy flow cytometry | ||||
| No. of participants | 12 | 12 | ||
| CD3+ CD8+ TIL (%) | 42 (1) | 29 (2) | 1 (0, 1) | .09 |
| CD3+ CD4+ TIL (%) | 30 (2) | 35 (1) | 1 (1, 2) | .43 |
| PD-1 + CD8+ TIL (%) | 47 (1) | 32 (3) | 1 (0, 1) | .31 |
| PD-1 + CD4+ TIL (%) | 37 (2) | 27 (2) | 1 (0, 1) | .11 |
| Tim3+ CD8+ TIL (%) | 3 (2) | 4 (3) | 1 (1, 2) | .24 |
| Tim3+ CD4+ TIL (%) | 3 (2) | 2 (2) | 1 (0, 1) | .34 |
| CD8+/CD4+ regulatory T cell | 16.0 (2.5) | 11.5 (2.2) | 0.7 (0.3, 1.6) | .36 |
| CTLA4+ CD8+ TIL (%) | 2 (2) | 1 (2) | 1 (1, 1) | .53 |
| LAG 3+ CD4+ TIL (%) | 15 (3) | 31 (3) | 2 (1, 3) | <.001 |
| iCOS+ CD4+ TIL (%) | 6 (2) | 5 (2) | 1 (0, 2) | .50 |
Note.—Marker values are geometric means, with geometric SD factors in parentheses. Differences are defined as post-TARE value divided by pre-TARE value and are shown with 95% CIs in parentheses. Log-transformed pre- and post-TARE values were compared using paired t tests. CTLA4 = cytotoxic T-lymphocyte–associated antigen 4, iCOS = inducible T-cell costimulator, IL = interleukin, LAG3 = lymphocyte activation gene 3, PD-1 = programmed cell death protein 1, TARE = transarterial radioembolization, TIL = tumor-infiltrating lymphocyte, Tim3 = T cell immunoglobulin and mucin domain 3.